Aprea Therapeutics, Inc.(APRE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

APRE Aprea Therapeutics, Inc.

盘后交易 05-06 18:09:16 EDT

0.8335

-0.0097

-1.15%

盘后0.8335

+0.00000.00%

16:04 EDT

最高0.9120	最低0.8014	成交量17.70万
今开0.8300	昨收0.8432	日振幅13.12%
总市值1,032万	流通市值724.76万	总股本1,238万
成交额14.67万	换手率2.04%	流通股本869.54万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"APRE","market":"US","secType":"STK","nameCN":"Aprea Therapeutics, Inc.","latestPrice":0.8335,"timestamp":1778097600000,"preClose":0.8432,"halted":0,"volume":176957,"hourTrading":{"tag":"盘后","latestPrice":0.8335,"preClose":0.8335,"latestTime":"16:04 EDT","volume":76,"amount":63.346000000000004,"timestamp":1778097842343,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01150379506641358,"floatShares":8695400,"shares":12382776,"eps":-1.93,"marketStatus":"盘后交易","change":-0.0097,"latestTime":"05-06 18:09:16 EDT","open":0.83,"high":0.912,"low":0.8014,"amount":146657.436907,"amplitude":0.131167,"askPrice":0.9047,"askSize":100,"bidPrice":0.7499,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.93,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1778112000000},"marketStatusCode":4,"adr":0,"listingDate":1570075200000,"exchange":"NASDAQ","adjPreClose":0.8432,"preHourTrading":{"tag":"盘前","latestPrice":0.8998,"preClose":0.8432,"latestTime":"08:48 EDT","volume":257,"amount":241.2606004,"timestamp":1778071719405,"change":0.0566,"changeRate":0.067125,"amplitude":0.059535},"postHourTrading":{"tag":"盘后","latestPrice":0.8335,"preClose":0.8335,"latestTime":"16:04 EDT","volume":76,"amount":63.346000000000004,"timestamp":1778097842343,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.457453,"impliedVol":4.309,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/APRE","defaultTab":"news","newsList":[{"id":"1109897242","title":"Aprea Therapeutics将在ASCO 2026年会公布Wee1抑制剂APR-1051的Acesot-1051一期临床试验进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1109897242","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109897242?lang=zh_cn&edition=full","pubTime":"2026-04-21 22:15","pubTimestamp":1776780912,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics宣布，将在2026年美国临床肿瘤学会（ASCO）年会上披露其创新药物APR-1051的最新临床数据。该药物作为Wee1抑制剂，目前正处于Acesot-1051一期临床试验阶段，此次更新将展示其在肿瘤治疗领域的潜在突破性进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175325317","title":"Aprea Therapeutics 公布Wee1抑制剂Apr-1051积极临床进展，在研I期试验中确认部分缓解","url":"https://stock-news.laohu8.com/highlight/detail?id=1175325317","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175325317?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:06","pubTimestamp":1774872399,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics公司近日公布了其Wee1抑制剂候选药物Apr-1051在正在进行的I期ACESOT-1051临床试验中展现出的积极初步临床活性。试验数据显示，该药物已在一名患者中观察到经确认的部分缓解，这标志着该药物研发的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198770926","title":"Aprea Therapeutics公布2025年第四季度及全年财务业绩并更新公司进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1198770926","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198770926?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:35","pubTimestamp":1773664502,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics, Inc.近日披露了其2025财年第四季度及全年的财务报告，并同步分享了公司最新的运营动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614277080","title":"Aprea Therapeutics, Inc.股价重挫10.11% 市值跌16.77万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614277080","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614277080?lang=zh_cn&edition=full","pubTime":"2026-02-27 01:18","pubTimestamp":1772126334,"startTime":"0","endTime":"0","summary":"北京时间2026年02月27日01时18分，Aprea Therapeutics, Inc.股票出现异动，股价大幅下挫10.11%。Aprea Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为2.32%。其相关个股中，Curanex Pharmaceuticals Inc、Klotho Neurosciences Inc C/Wts 21/06/2029 、Liminatus Pharma Inc C/Wts 30/04/2030 涨幅较大，Curanex Pharmaceuticals Inc、Kairos Pharma, Ltd.、Cardio Diagnostics Holdings Inc.较为活跃，换手率分别为635.32%、99.04%、98.81%，振幅较大的相关个股有Curanex Pharmaceuticals Inc、Briacell Therapeutics Corp C/Wts 26/02/2026、Klotho Neurosciences Inc C/Wts 21/06/2029 ，振幅分别为59.81%、53.95%、50.06%。Aprea Therapeutics, Inc.公司简介：Aprea Therapeutics Inc是一家临床生物制药公司，致该小组通过合成的致死率专注于精确肿瘤学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022701185497a73185&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022701185497a73185&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","LENZ","APRE","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117590352","title":"Aprea Therapeutics公司：220毫克剂量水平观察到肿瘤缩小50%及CA-125生物标志物显著降低","url":"https://stock-news.laohu8.com/highlight/detail?id=1117590352","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117590352?lang=zh_cn&edition=full","pubTime":"2026-02-18 21:03","pubTimestamp":1771419793,"startTime":"0","endTime":"0","summary":"在最新临床研究中，Aprea Therapeutics公司采用220毫克剂量治疗方案取得突破性进展。该剂量水平不仅实现肿瘤体积缩小达50%的显著效果，更令人瞩目的是观察到CA-125生物标志物水平的实质性下降。这一双重积极指标为卵巢癌等恶性肿瘤的靶向治疗开辟了新路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157749062","title":"Aprea Therapeutics宣布Wee1抑制剂Apr-1051取得新进展，ACESOT-1051试验中观察到第二例部分缓解","url":"https://stock-news.laohu8.com/highlight/detail?id=1157749062","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157749062?lang=zh_cn&edition=full","pubTime":"2026-02-18 21:01","pubTimestamp":1771419674,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics公司近日公布了其Wee1抑制剂候选药物Apr-1051的最新积极临床数据。在正在进行的ACESOT-1051临床试验中，研究观察到了额外的临床活性信号，其中包括第二例达到部分缓解（Partial Response）的病例。这一进展进一步支持了Apr-1051在目标患者群体中的治疗潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104981388","title":"Aprea Therapeutics强化DDR抗癌疗法全球专利布局，为管线拓展铺平道路","url":"https://stock-news.laohu8.com/highlight/detail?id=1104981388","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104981388?lang=zh_cn&edition=full","pubTime":"2026-02-12 10:23","pubTimestamp":1770862993,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics公司近日宣布其DNA损伤应答（DDR）抗癌疗法全球专利组合实现重要拓展，这一战略举措将为公司研发管线的持续增长奠定坚实基础。通过加强知识产权保护，该公司在肿瘤治疗领域的技术壁垒得到进一步巩固，为未来创新疗法的商业化进程提供了有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134539572","title":"Aprea Therapeutics 宣布在评估Wee1抑制剂APR-1051的ACESOT-1051剂量递增试验中取得早期临床概念验证，首次扫描即观察到部分缓解","url":"https://stock-news.laohu8.com/highlight/detail?id=1134539572","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134539572?lang=zh_cn&edition=full","pubTime":"2026-01-29 21:31","pubTimestamp":1769693485,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics, Inc. 近日公布，其正在进行的ACESOT-1051剂量递增试验已获得早期临床概念验证数据。该试验旨在评估其Wee1抑制剂候选药物APR-1051。令人鼓舞的是，在首次疗效评估扫描中，已观察到一例患者出现部分缓解，这为药物的抗肿瘤活性提供了初步的积极信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131666754","title":"Aprea Therapeutics公司：2026年上半年将发布更多进展，年内完成剂量递增研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1131666754","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131666754?lang=zh_cn&edition=full","pubTime":"2026-01-29 21:29","pubTimestamp":1769693350,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics公司宣布，将在2026年上半年披露更多研发进展，并计划于同年晚些时候完成其正在进行的剂量递增研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109491456","title":"Aprea Therapeutics, Inc. - 提交股东5.5百万股的再销售招股说明书 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1109491456","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109491456?lang=zh_cn&edition=full","pubTime":"2025-12-20 05:14","pubTimestamp":1766178871,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics, Inc. - 提交股东5.5百万股的再销售招股说明书 - SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147401439","title":"Aprea Therapeutics首席执行官致股东信，强调2025年管线进展及2026年展望","url":"https://stock-news.laohu8.com/highlight/detail?id=1147401439","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147401439?lang=zh_cn&edition=full","pubTime":"2025-12-18 21:30","pubTimestamp":1766064622,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics首席执行官致股东信，强调2025年管线进展及2026年展望","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584600792","title":"Aprea Therapeutics, Inc.2025财年第三财季实现净利润-2.97百万美元，同比增加21.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584600792","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584600792?lang=zh_cn&edition=full","pubTime":"2025-11-18 10:00","pubTimestamp":1763431244,"startTime":"0","endTime":"0","summary":"11月18日，Aprea Therapeutics, Inc.公布财报，公告显示公司2025财年第三财季净利润为-2.97百万美元，同比增加21.43%；其中营业收入为1848.00美元，同比减少99.48%，每股基本收益为-0.47美元。机构评级：截至2025年11月18日，当前有2家机构对Aprea Therapeutics, Inc.目标价做出预测，其中目标均价为10.50美元，其中最低目标价为10.00美元，最高目标价为11.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111810005197700d1b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111810005197700d1b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518627618","title":"Aprea Therapeutics, Inc.盘中异动 股价大涨6.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518627618","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518627618?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:24","pubTimestamp":1741616689,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时24分，Aprea Therapeutics, Inc.股票出现异动，股价快速上涨6.27%。Aprea Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.52%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Aeon Biopharma, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为3414.97%、722.01%、415.62%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Biodexa Pharmaceuticals Plc，振幅分别为41.36%、40.24%、39.34%。Aprea Therapeutics, Inc.公司简介：Aprea Therapeutics Inc是一家临床生物制药公司，致该小组通过合成的致死率专注于精确肿瘤学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022244998a2aa2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022244998a2aa2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["APRE","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514869463","title":"Aprea Therapeutics, Inc.盘中异动 急速上涨5.20%报2.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514869463","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514869463?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:49","pubTimestamp":1740667763,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时49分，Aprea Therapeutics, Inc.股票出现波动，股价急速拉升5.20%。Aprea Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.89%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Nutriband Inc C/Wts 、Tiziana Life Sciences Ltd涨幅较大，Quoin Pharmaceuticals Ltd、Moleculin Biotech, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为471.13%、96.23%、84.99%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Biorestorative Therapies, Inc.、Tevogen Bio Holdings Inc C/Wts 14/02/2029 ，振幅分别为59.85%、30.36%、21.99%。Aprea Therapeutics, Inc.公司简介：Aprea Therapeutics Inc是一家临床生物制药公司，致该小组通过合成的致死率专注于精确肿瘤学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227224923abdf7328&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227224923abdf7328&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514090349","title":"Aprea Therapeutics, Inc.盘中异动 早盘快速上涨5.88%报2.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514090349","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514090349?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:35","pubTimestamp":1740494150,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时35分，Aprea Therapeutics, Inc.股票出现波动，股价快速拉升5.88%。Aprea Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.44%。其相关个股中，Moleculin Biotech, Inc.、Silexion Therapeutics Corp、Adial Pharmaceuticals, Inc涨幅较大，Gt Biopharma, Inc.、Moleculin Biotech, Inc.、Adial Pharmaceuticals, Inc较为活跃，换手率分别为774.32%、490.60%、259.23%，振幅较大的相关个股有Adial Pharmaceuticals, Inc、Gt Biopharma, Inc.、Moleculin Biotech, Inc.，振幅分别为20.51%、18.23%、15.89%。Aprea Therapeutics, Inc.公司简介：Aprea Therapeutics Inc是一家临床生物制药公司，致该小组通过合成的致死率专注于精确肿瘤学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223550962ff385&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223550962ff385&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","APRE","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513722499","title":"Aprea Therapeutics, Inc.盘中异动 早盘急速上涨5.92%报2.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513722499","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513722499?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:35","pubTimestamp":1740407705,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时35分，Aprea Therapeutics, Inc.股票出现异动，股价快速拉升5.92%。Aprea Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。其相关个股中，Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Psyence Biomedical Ltd C/Wts 25/01/2029、Addex Therapeutics Limited涨幅较大，Aditxt, Inc.、Biodexa Pharmaceuticals Plc、Acurx Pharmaceuticals, Inc.较为活跃，换手率分别为42.24%、24.21%、17.78%，振幅较大的相关个股有Telix Pharmaceutic、Gossamer Bio, Inc.、Summit Therapeutics Inc.，振幅分别为15.85%、14.69%、14.51%。Aprea Therapeutics, Inc.公司简介：Aprea Therapeutics Inc是一家临床生物制药公司，致该小组通过合成的致死率专注于精确肿瘤学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223505abdb0eb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223505abdb0eb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","APRE","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512143665","title":"Aprea Therapeutics, Inc.盘中异动 股价大跌5.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512143665","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512143665?lang=zh_cn&edition=full","pubTime":"2025-02-20 03:34","pubTimestamp":1739993691,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日03时34分，Aprea Therapeutics, Inc.股票出现波动，股价急速下挫5.44%。Aprea Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.51%。其相关个股中，Surrozen Inc C/Wts 01/08/2031 、Osr Holdings, Inc.、Osr Holdings Inc C/Wts 02/09/2028 涨幅较大，Aditxt, Inc.、Alzamend Neuro, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为688.41%、255.53%、231.18%，振幅较大的相关个股有Surrozen Inc C/Wts 01/08/2031 、Osr Holdings Inc C/Wts 02/09/2028 、Osr Holdings, Inc.，振幅分别为280.70%、267.43%、159.49%。Aprea Therapeutics, Inc.公司简介：Aprea Therapeutics Inc是一家临床生物制药公司，致该小组通过合成的致死率专注于精确肿瘤学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220033451a24c3162&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220033451a24c3162&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["APRE","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510333469","title":"Aprea Therapeutics, Inc.盘中异动 股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510333469","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510333469?lang=zh_cn&edition=full","pubTime":"2025-02-11 23:05","pubTimestamp":1739286310,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日23时05分，Aprea Therapeutics, Inc.股票出现波动，股价急速下挫5.01%。Aprea Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.41%。其相关个股中，Ocean Biomedical, Inc.、Dominari Holdings Inc.、Lipella Pharmaceuticals Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为2491.97%、706.54%、319.82%，振幅较大的相关个股有Dominari Holdings Inc.、In8Bio, Inc.、Ocean Biomedical, Inc.，振幅分别为45.29%、37.99%、33.04%。Aprea Therapeutics, Inc.公司简介：Aprea Therapeutics Inc是一家临床生物制药公司，致该小组通过合成的致死率专注于精确肿瘤学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211230510961f4e1e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211230510961f4e1e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["APRE","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509775210","title":"Aprea Therapeutics, Inc.盘中异动 急速跳水5.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509775210","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509775210?lang=zh_cn&edition=full","pubTime":"2025-02-08 04:21","pubTimestamp":1738959661,"startTime":"0","endTime":"0","summary":"北京时间2025年02月08日04时21分，Aprea Therapeutics, Inc.股票出现波动，股价大幅下跌5.66%。Aprea Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.76%。其相关个股中，Conduit Pharmaceuticals Inc.、Surrozen Inc C/Wts 01/08/2031 、Sionna Therapeutics, Inc.涨幅较大，Conduit Pharmaceuticals Inc.、Tonix Pharmaceuticals Holding Corp.、Lipella Pharmaceuticals Inc.较为活跃，换手率分别为8972.52%、184.16%、164.09%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Conduit Pharmaceuticals Inc.、Lexaria Bioscience Corp C/Wts 14/01/2026 ，振幅分别为130.43%、93.55%、66.67%。Aprea Therapeutics, Inc.公司简介：Aprea Therapeutics Inc是一家临床生物制药公司，致该小组通过合成的致死率专注于精确肿瘤学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208042101abc673c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208042101abc673c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509282353","title":"Aprea Therapeutics, Inc.盘中异动 股价大涨10.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509282353","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509282353?lang=zh_cn&edition=full","pubTime":"2025-02-05 22:31","pubTimestamp":1738765896,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日22时31分，Aprea Therapeutics, Inc.股票出现波动，股价快速拉升10.26%。Aprea Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.80%。其相关个股中，Oragenics Inc.、Pasithea Therapeutics Corp.、Pasithea Therapeutics Corp C/Wts 12/08/2026 涨幅较大，Pasithea Therapeutics Corp.、60 Degrees Pharmaceuticals, Inc.、Oragenics Inc.较为活跃，换手率分别为2623.10%、595.04%、582.54%，振幅较大的相关个股有Pasithea Therapeutics Corp.、Eyepoint Pharmaceuticals, Inc.、Oragenics Inc.，振幅分别为16.82%、11.68%、9.75%。Aprea Therapeutics, Inc.公司简介：Aprea Therapeutics Inc是一家临床生物制药公司，致该小组通过合成的致死率专注于精确肿瘤学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205223136a23a7a50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205223136a23a7a50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aprea.com","stockEarnings":[{"period":"1week","weight":0.0075},{"period":"1month","weight":0.1786},{"period":"3month","weight":0.2585},{"period":"6month","weight":-0.2973},{"period":"1year","weight":-0.5182},{"period":"ytd","weight":-0.0115}],"compareEarnings":[{"period":"1week","weight":0.017},{"period":"1month","weight":0.1036},{"period":"3month","weight":0.0548},{"period":"6month","weight":0.0798},{"period":"1year","weight":0.2844},{"period":"ytd","weight":0.0614}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Aprea Therapeutics, Inc.于2019年5月根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，致力于开发和商业化新型癌症疗法，重新激活突变型p53肿瘤抑制蛋白。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.06034},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.033286},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.111168},{"month":4,"riseRate":0.142857,"avgChangeRate":-0.117728},{"month":5,"riseRate":0.142857,"avgChangeRate":-0.103034},{"month":6,"riseRate":0.333333,"avgChangeRate":0.023066},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.044399},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.005221},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.052829},{"month":10,"riseRate":0.333333,"avgChangeRate":0.013865},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.091344},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.053133}],"exchange":"NASDAQ","name":"Aprea Therapeutics, Inc.","nameEN":"Aprea Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aprea Therapeutics, Inc.(APRE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Aprea Therapeutics, Inc.(APRE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Aprea Therapeutics, Inc.,APRE,Aprea Therapeutics, Inc.股票,Aprea Therapeutics, Inc.股票老虎,Aprea Therapeutics, Inc.股票老虎国际,Aprea Therapeutics, Inc.行情,Aprea Therapeutics, Inc.股票行情,Aprea Therapeutics, Inc.股价,Aprea Therapeutics, Inc.股市,Aprea Therapeutics, Inc.股票价格,Aprea Therapeutics, Inc.股票交易,Aprea Therapeutics, Inc.股票购买,Aprea Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aprea Therapeutics, Inc.(APRE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Aprea Therapeutics, Inc.(APRE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}